NCT06451302View on ClinicalTrials.gov

Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Ewing SarcomaRisk Stratification
Interventions
DRUG

cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide

The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Yizhuo Zhang

OTHER

NCT06451302 - Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study | Biotech Hunter | Biotech Hunter